New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae Pneumonia)
NCT ID: NCT00035269
Last Updated: 2011-04-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
230 participants
INTERVENTIONAL
2001-12-31
2003-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Effectiveness, Safety, and Microbiology Study of Doripenem in Patients With Nosocomial (Hospital-acquired) Pneumonia
NCT00502801
A P3 Comparator Trial in Community Acquired Bacterial Pneumonia
NCT02269644
A Controlled Human Pneumococcal Infection Model (PIM) Study
NCT05361499
Doripenem in the Treatment of Hospital-Acquired Pneumonia
NCT00211003
T2Bacteria Panel Pivotal Study
NCT02535468
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Antibiotic
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The patient must have S. pneumoniae (a specific bacteria) growing in sputum or blood to continue treatment.
Exclusion Criteria
* Patients with HIV and a low CD4 count are excluded.
13 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Center
Los Angeles, California, United States
Research Center
Jacksonville, Florida, United States
Research Center
Naples, Florida, United States
Research Center
Savannah, Georgia, United States
Research Center
Springfield, Illinois, United States
Research Center
Baton Rouge, Louisiana, United States
Research Center
Baltimore, Maryland, United States
Research Center
Ann Arbor, Michigan, United States
Research Center
Royal Oak, Michigan, United States
Research Center
Springfield, Missouri, United States
Research Center
Hackensack, New Jersey, United States
Research Center
Newark, New Jersey, United States
Research Center
Somerville, New Jersey, United States
Research Center
Staten Island, New York, United States
Research Center
Stony Brook, New York, United States
Research Center
Columbus, Ohio, United States
Research Center
Zanesville, Ohio, United States
Research Center
Fleetwood, Pennsylvania, United States
Research Center
Hershey, Pennsylvania, United States
Research Center
Ninety Six, South Carolina, United States
Research Center
Spartanburg, South Carolina, United States
Research Center
Harrogate, Tennessee, United States
Research Center
Jackson, Tennessee, United States
Research Center
Knoxville, Tennessee, United States
Research Center
Memphis, Tennessee, United States
Research Center
Memphis, Tennessee, United States
Research Center
Memphis, Tennessee, United States
Research Center
Nashville, Tennessee, United States
Research Center
Dallas, Texas, United States
Research Center
Houston, Texas, United States
Research Center
Lubbock, Texas, United States
Research Center
Charlottesville, Virginia, United States
Research Center
Richmond, Virginia, United States
Research Center
Seattle, Washington, United States
Research Center
Bratislava, , Slovakia
Research Center
Barcelona, Barcelona, Spain
Research Center
Barcelona, Barcelona, Spain
Research Center
Barcelona, Barcelona, Spain
Research Center
Mataró, Barcelona, Spain
Research Center
Girona, Girona, Spain
Research Center
Madrid, Madrid, Spain
Research Center
Madrid, Madrid, Spain
Research Center
Madrid, Madrid, Spain
Research Center
Móstoles, Madrid, Spain
Research Center
Kaohsiung City, , Taiwan
Research Center
Taoyuan District, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A5951056
Identifier Type: -
Identifier Source: secondary_id
M12600071
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.